natgillin/translations-raw huggingface dataset:
Serious adverse reactions affecting the nervous system have been reported spontaneously in association with modafinil, including cerebrovascular disorders, convulsions and extrapyramidal symptoms.
V spontanih poročilih so bili v zvezi z modafinilom navedeni resni neželeni učinki, ki vplivajo na živčevje, vključno s cerebrovaskularnimi boleznimi, konvulzijami in ekstrapiramidalnimi simptomi.
[See Annex I - To be completed nationally] {Name and address} <{tel}> <{fax}> <{e-mail}>
[Glejte Dodatek I - podatke je treba dopolniti v posameznih državah.]
The signs may include: o mood swings or abnormal thinking, o aggression or hostility, o forgetfulness or confusion, o feeling of extreme happiness, o over-excitement or hyperactivity, o anxiety or nervousness, o depression, suicidal thoughts or behaviour, o agitation or psychosis (a loss of contact with reality which may include delusions or sensing things that are not real), feeling detached or numb, or personality disorder.
Ti znaki lahko vključujejo: o nihanje razpoloženja ali nenormalno razmišljanje; o agresijo ali sovražnost; o pozabljivost ali zmedenost; o občutek ekstremne sreče; o pretirano vzburjenost ali hiperaktivnost; o tesnobnost ali nervoznost; o depresijo, samomorilne misli ali vedenje;
Blood pressure and heart rate should be regularly monitored in patients receiving modafinil.
Pri bolnikih, ki jemljejo modafinil, naj se redno nadzorujeta krvni tlak in utrip.
Suicide-related behaviour (including suicide attempts and suicidal ideation) has been reported in patients treated with modafinil.
Pri bolnikih, zdravljenih z modafinilom, so poročali o s samomorom povezanem vedenju (vključno s poskusi samomora in samomorilnimi mislimi).
Important information about some of the ingredients of Modafinil containing medicinal products [To be completed nationally].
Pomembne informacije o nekaterih sestavinah zdravil, ki vsebujejo modafinil [Izpolni država članica]
Following a request from the MAH, the CHMP convened a Scientific Advisory Group (SAG) CNS during the re-examination procedure.
CHMP je v postopku ponovnega pregleda po zahtevku imetnika dovoljenja za promet z zdravilom sklical znanstveno svetovalno skupino (SAG) za klinično nevrologijo.
• Have an irregular heartbeat.
• če imate nereden srčni utrip;
The following adverse reactions have been reported in clinical trials and/or post-marketing experience.
V kliničnih preskušanjih in/ali izkušnjah po dajanju zdravila v promet so poročali o naslednjih neželenih učinkih.
Rare cases of serious or life-threatening rash, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide post-marketing experience.
Poročali so o redkih primerih smrtno nevarnega izpuščaja, vključno s Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo ter o izpuščaju zaradi zdravil z eozinofilijo in sistemskimi simptomi pri otrocih in odraslih po postmarketinških izkušnjah z vsega sveta.
A total of 16 cases of Stevens Johnson Syndrome/Toxic Epidermal Necrolysis/Erythema Multiforme have been reported in a post-marketing setting.
V obdobju trženja zdravila so poročali o 16 primerih Stevens-Johnsonovega sindroma ali toksične epidermalne nekrolize ali mutiformnega eritema.
General disorders and administration site conditions Common: asthenia, chest pain Uncommon: peripheral oedema, thirst
Splošne težave in spremembe na mestu aplikacije Pogosti: astenija, bolečina v prsnem košu Občasni: periferni edem, žeja
Musculoskeletal and connective tissue disorders Uncommon: back pain, neck pain, myalgia, myasthenia, leg cramps, arthralgia, twitch
Bolezni mišično-skeletnega sistema in vezivnega tkiva Občasni: bolečine v hrbtu, bolečine v vratu, mialgija, miastenija, krči v nogah, artralgija, trzanje
Uncommon: sleep disorder, emotional lability, decreased libido, hostility, depersonalisation, personality disorder, abnormal dreams, agitation, aggression, suicidal ideation.
Pogosti: nervoza, insomnija, anksioznost, depresija, nenormalno mišljenje, zmedenost Občasni: motnje spanja, čustvena labilnost, zmanjšan libido, sovražnost, depersonalizacija, osebnostna motnja, nenormalne sanje, agitacija, agresija, samomorilne misli Redki: halucinacije, manija, psihoza
• Calcium channel blockers or beta-blockers for high blood pressure or heart problems (e.g. amlodipine, verapamil or propranalol).
Med zdravljenjem bo vaš zdravnik nadzoroval čas strjevanja krvi; - zaviralce kalcijevih kanalčkov ali zaviralce receptorjev beta za visok krvni tlak ali težave s srcem (npr. amlodipin, verapamil ali propranalol); - statine za zniževanje ravni holesterola (npr. atorvastatin ali simvastatin).
Abuse, misuse and diversion
Zloraba, napačna uporaba in rekreativna uporaba
Particularly for serious skin disorders, data is indicative of a higher incidence in the paediatric population.
Podatki kažejo večjo pojavnost v pediatrični populaciji, zlasti resnih kožnih bolezni.
Cardiovascular adverse events such as hypertension and arrhytmias are documented in association with modafinil.
Dokumentirana je povezava med modafinilom in srčno-žilnimi dogodki, kot so hipertenzija in aritmije.
Serious nervous system and psychiatric related events such as suicidal ideation, psychotic episodes, and depression have also been identified in association to modafinil.
Z modafinilom so povezani tudi resni učinki na živčevje in psihiatrični učinki, kot so samomorilne misli, psihotične epizode in depresija.
Gonzagagasse 16/16, 1010, Vienna, Austria
Torrex Chiesi Pharma GmbH, Gonzagagasse 16/16, 1010, Vienna,
Cephalon GmbH Landsberger Straße 94 80339 München, Germany
Cephalon GmbH Landsberger Straße 94
Bipolar disorders
Bipolarne motnje
CEPHALON France 20, rue Charles Martigny 94701 Maisons-Alfort Cedex
CEPHALON France 20, rue Charles Martigny 94701 Maisons-Alfort Cedex France
Uncommon: sweating, rash, acne, pruritis
Občasni: potenje, izpuščaj, akne, pruritus
The dosage of modafinil should be reduced by half in patients with severe hepatic impairment.
Pri bolnikih s hudo jetrno okvaro je treba odmerek modafinila prepoloviti.
Product name Strength Pharmaceutical form
Farmacevtska oblika
BEFORE YOU TAKE MODAFINIL CONTAINING MEDICINAL PRODUCTS
SHRANJEVANJE ZDRAVIL, KI VSEBUJEJO MODAFINIL
Serious rash requiring hospitalisation and discontinuation of treatment has been reported with the use of modafinil occurring within 1 to 5 weeks after treatment initiation.
Hudi izpuščaji, vključno s Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo in izpuščajem zaradi zdravil z eozinofilijo in sistemskimi simptomi Pri uporabi modafinila so poročali o hudem izpuščaju, ki je zahteval hospitalizacijo in prekinitev zdravljenja, pojavil pa se je od enega do pet tednov po začetku zdravljenja.
Take special care with Modafinil containing medicinal products if you
Bodite posebno pozorni pri uporabi zdravil, ki vsebujejo modafinil:
ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA IN NAVODILO ZA UPORABO
HOW TO TAKE MODAFINIL CONTAINING MEDICINAL PRODUCTS Always take Modafinil containing medicinal products exactly as your doctor has told you.
Pri jemanju zdravil, ki vsebujejo modafinil, natančno upoštevajte zdravnikova navodila.
MODIODAL 100 mg tablets
MODIODAL 100 mg/tabl tablete
The higher rate of adverse events observed in the modafinil group during the OSA trials is of particular concern, given the known cardiovascular risks in this population.
Glede na znana tveganja srčno-žilnih bolezni v tej populaciji je zlasti problematična višja stopnja neželenih učinkov v skupini, ki je prejemala modafinil med preskušanji pri OSA.
Numbness or tingling of the hands or feet (‘pins and needles').
materničnimi vložki (IUV) in obliži).
NAME OF THE MEDICINAL PRODUCT Modafinil - containing medicinal products (see Annex I) products 100 mg tablets Modafinil - containing medicinal products (see Annex I) products 200 mg tablets See Annex I - To be completed nationally.
Zdravila, ki vsebujejo modafinil (glejte Dodatek I) 100 mg tablete.
The effects of Balaxur were first tested in experimental models before being studied in humans.
Učinki zdravila Balaxur so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The company that applied for authorisation is Merz Pharmaceuticals GmbH, Germany.
Zahtevo za dovoljenje za promet z zdravilom je vložila nemška družba Merz Pharmaceuticals GmbH.
The company informed the CHMP that there are no patients currently included in clinical trials with Balaxur in the European Union.
Družba je odbor CHMP obvestila, da v Evropski uniji v klinična preskušanja zdravila Balaxur trenutno ni vključenih bolnikov.
Balaxur is a medicine that contains two active substances, memantine hydrochloride and donepezil hydrochloride.
Balaxur je zdravilo, ki vsebuje dve zdravilni učinkovini, memantinijev hidroklorid in donepezilijev hidroklorid.
On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Balaxur, intended for the treatment of moderate to moderately severe Alzheimer's disease in patients who are already taking memantine and donepezil.
Odbor za zdravila za uporabo v humani medicini (CHMP) je 18. oktobra 2012 sprejel negativno mnenje, s katerim priporoča zavrnitev odobritve dovoljenja za promet z zdravilom Balaxur, ki naj bi se uporabljalo za zdravljenje zmerne do zmerno hude Alzheimerjeve bolezni pri bolnikih, ki že prejemajo memantin in donepezil.
Therefore, the CHMP was of the opinion that the benefits of Balaxur did not outweigh its risks and recommended that it be refused marketing authorisation.
Posledično je odbor CHMP menil, da koristi zdravila Balaxur ne odtehtajo z njim povezanih tveganj, zato je priporočil zavrnitev dovoljenja za promet z zdravilom.
Balaxur is a combination treatment containing two active substances which are already authorised in the EU to treat the symptoms of Alzheimer's disease.
Zdravilo Balaxur je kombinirano zdravilo z dvema zdravilnima učinkovinama, ki sta v EU že odobreni za zdravljenje simptomov Alzheimerjeve bolezni.
What is Balaxur?
Kaj je zdravilo Balaxur?
Balaxur was expected to be used to treat moderate to moderately severe Alzheimer's disease, in patients who are already taking a daily dose of 20 mg memantine and 10 mg donepezil.
Zdravilo Balaxur naj bi se uporabljalo za zdravljenje zmerne do zmerno hude Alzheimerjeve bolezni pri bolnikih, ki že prejemajo dnevni odmerek 20 mg memantina in 10 mg donepezila.
What was Balaxur expected to be used for?
Za kaj naj bi se zdravilo Balaxur uporabljalo?
How is Balaxur expected to work?
Kako naj bi zdravilo Balaxur delovalo?
Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease, and over-activity of the NMDA receptors can result in cell damage or death.
Spremembe načina, kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršna je pri Alzheimerjevi bolezni, prekomerna aktivnost receptorjev
90 (3 x 30) tablets (multipack)
90 (3 x 30) tablet (skupna pakiranja)
Do not use on canaries.
Ne uporabljajte pri kanarčkih.
Imidacloprid is toxic for birds, especially canaries.
Imidakloprid je toksičen za ptice, zlasti za kanarčke.
Date of first authorisation: 02/04/2003.
Datum pridobitve dovoljenja za promet: 02/04/2003.
ATCvet code: QP54AB52.
Oznaka ATC vet: QP54AB52.
These signs disappear without further treatment.
Ti znaki izginejo brez nadaljnjega zdravljenja.
Wash hands thoroughly after use.
Po dajanju si temeljito umijte roke.
In the study these reactions were common (seen in 2 of 106 treated dogs).
V raziskavah so bile take reakcije pogoste (pri 2 od 106 zdravljenih psih).
It is a parasiticide which is active against many internal and external parasites.
Je paraziticid, ki deluje na mnoge notranje in zunanje zajedavce.
It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.
Priporočljivo je preprečiti avto-koprofagijo med obema zdravljenjema, da preprečimo morebitno ponovno okužbo.
Date of last renewal: 14/01/2013.
Datum zadnjega podaljšanja dovoljenja za promet: 14/01/2013.
Do not eat, drink or smoke during application.
Med nanosom ne jejte, pijte in kadite.
Efficacy against adult Dirofilaria repens has not been tested under field conditions.
Učinkovitost proti odraslim oblikam Dirofilaria repens v terenskih razmerah ni bila testirana.
Apply only to undamaged skin.
Nanašajte le na nepoškodovano kožo.
Especially severe cases may require more prolonged and more frequent treatment.
V primeru hudih okužb je potrebno podaljšano in pogostejše zdravljenje.
Microfilaria
mikrofilarije
The safety of the product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study.
Varnost zdravila pri dirofilariozi je bila ocenjena le pri psih, klasificiranih kot razred 1 ali 2 v laboratorijskih študijah in pri nekaterih psih razreda 3 v terenskih študijah.
See sections 4.5 and 6.6.
Glejte poglavji 4.5 in 6.6.
Weight of dog [kg]
Teža psa [kg]
The product's efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals.
Testiranje učinkovitosti zdravila ni bilo opravljeno na belih dihurjih, težjih od 2 kg, zato je pri njih lahko učinkovanje zdravila krajše.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Priporočamo pregled pri veterinarju 30 dni po dajanju zdravila, ker bo pri nakaterih živalih potrebno zdravljenje ponoviti.
Avoid contact with skin, eyes or mouth.
Preprečite stik pripravka s kožo, očmi ali usti.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
- zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Following absorption from the skin, moxidectin is distributed systemically throughout the body tissues but due to its lipophilicity it is concentrated mainly in the fat.
Po absorpciji s kože, moksidetin deluje sistemsko ter se porazdeli po telesnih tkivih, vendar se zaradi svoje lipofilnosti koncentrira predvsem v maščobi.
There is no known specific antidote.
Protistrup ni znan.
The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases.
Enkraten odmerek na 4 tedne v obdobju 2 do 4 mesecev, uspešno deluje proti Demodex canis in vidno izboljša klinično stanje pri blagih do zmernih okužbah.
Advocate should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Zdravilo Advocate ne sme priti v vodotoke, ker je lahko nevaren za ribe in druge vodne organizme.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Ne uporabite v primerih preobčutljivosti na učinkovino(e) ali na katero koli pomožno snov.
Apply topically to the skin between the shoulder blades.
Nanašajte na kožo med lopaticama.
In these severe cases concomitant supportive treatment is necessary as treatment with the product alone may not be sufficient to prevent death of the animal.
V teh posameznih hudih primerih je podporna terapija nujna, saj zdravljenje le s tem zdravilom ne bo zadostovalo za preprečitev možne smrti.
Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group.
Pri obolenjih, povzročenih z Dirofilaria immitis, zdravila ne dajemo pri psih, klasificiranih kot razred 4, ker varnost tega zdravila ni bila ocenjena pri tej skupini živali.
Dosage schedule for cats:
Odmerjanje za mačke:
Therefore the use in dogs with obvious or severe symptoms of the disease should be based on a careful benefit-risk assessment by the treating veterinarian.
Zaradi tega mora biti uporaba zdravila pri psih, ki imajo očitne ali hude simptome, v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
The use of activated charcoal may be beneficial.
Pomaga lahko dajanje aktivnega oglja.
Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ectoparasiticide belonging to the chloronicotinyl group of compounds.
Imidakloprid 1-(6-kloro-3-piridilmetil) N-nitroimidazolidin-2-ilideneamin je ektoparaziticid iz skupine kloronikotinilov.
If the animal licks the application site after treatment, neurological signs (most of which are transient) may be observed in very rare cases (see section 4.10).
Če žival poliže mesto aplikacije po zdravljenju, se lahko v zelo redkih primerih pojavijo nevrološki znaki (večina jih je prehodnih) (glejte poglavje 4.10).
Do not use in puppies under 7 weeks of age.
Zdravila ne dajemo pasjim mladičem, mlajšim od 7 tednov.
To establish a treatment routine, it is recommended that the same day or date be used each month.
Najbolje je, da zdravilo nanašamo vsak mesec na isti datum ali dan v tednu.
No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed.
Medsebojnega delovanja zdravila Advocate z zdravili za uporabo v veterinarski medicini, ki se rutinsko uporabljajo, ali z medicinskimi ali kirurškimi posegi niso opazili.
• the treatment of Angiostrongylus vasorum and Crenosoma vulpis,
• zdravljenje Angiostrongylus vasorum in Crenosoma vulpis,
Imidacloprid has a high affinity for the nicotinergic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS) of the flea.
Imidakloprid ima visoko afiniteto za nikotinergične acetilholin receptorje v postsinaptičnem delu osrednjega živčevja pri bolhah.
Treatment of microfilariae (D. immitis)
Zdravljenje mikrofilarij (D.immitis)
Treatment of demodicosis (caused by Demodex canis)
Zdravljenje demodikoze, ki jo povzroča Demodex canis
Treatment and prevention of Angiostrongylus vasorum
Zdravljenje in preprečevanje infestacij z Angiostrongylus vasorum
Chemically, it is more accurately described as a chloronicotinyl nitroguanidine.
Po kemični sestavi ga lahko razvrstimo kot kloronikotinil nitroguanidin.
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins.
Farmakoterapevtska skupina: Antiparazitiki, insekticidi in repelenti, makrociklični laktoni, milbemicini.
The treatment schedule should be based on individual veterinary diagnosis and on the local epidemiological situation.
Shema zdravljenja poteka glede na individualne diagnoze veterinarja in glede na lokalne epidemiološke razmere.
For ferrets: Do not use Advocate for dogs.
Za bele dihurje: Ne dajemo zdravila Advocate za pse.
If the product accidentally gets into eyes, they should be thoroughly flushed with water.
Če zdravilo pride v stik z očmi, jih temeljito sperite z vodo.
The drug has a persistent action and protects dogs for 4 weeks after a single application against reinfection with the following parasites: Dirofilaria immitis, Dirofilaria repens, Angiostrongylus vasorum.
Učinkovina je dolgo delujoča in psa še štiri tedne po enkratnem nanosu ščiti pred ponovno okužbo z naslednjimi paraziti: Dirofilaria immitis, Dirofilaria repens, Angiostrongylus vasorum.
• the prevention of spirocercosis (Spirocerca lupi),
• preprečevanje spirocerkoze (Spirocerca lupi),
Do not use in kittens under 9 weeks of age.
Zdravila ne dajemo mačjim mladičem, mlajšim od 9 tednov.
B. CONDITIONS OR RESTRICTIONSREGARDING SUPPLY AND USE
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
This is not a sign of intoxication and disappears within some minutes without treatment.
To ni znak zastrupitve, živali se po nekaj minutah nehajo sliniti, ne da bi jih zdravili.
The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.
Zdravljenje naj se nadaljuje v rednih mesečnih intervalih še najmanj 1 mesec po zadnji izpostavljenosti komarjem
When the product is applied in 3 to 4 separate spots (see section 4.9), specific care should be taken to prevent the animal licking the application sites.
Če zdravilo nanesemo na 3 do 4 različna mesta (glej poglavje 4.9) pazimo, da žival ne liže mesto nanosa.
White polypropylene unit dose pipette with screw cap.
bela polipropilenska merilna kapalka za enkratno dajanje s pokrovom z navojem.
There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a benefit-risk assessment for these animals.
Ker so izkušnje pri uporabi zdravila pri bolnih in šibkih živalih omejene, uporabite zdravilo pri teh živalih na osnovi ocene korist/tveganje.
Moxidectin, 23-(O-methyloxime)-F28249 alpha is a second-generation macrocyclic lactone of the milbemycin family.
Moksidektin 23-(O-methyloxime)-F28249 alfa je makrociklični lakton druge generacije in spada v skupino milbemicinov.
Wherever possible apply to undamaged skin.
Če je le mogoče, koža naj ne bo poškodovana.
4.2 Indications for use, specifying the target species For dogs suffering from, or at risk from, mixed parasitic infections:
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Za pse, ki imajo ali so izpostavljeni mešanim parazitarnim infestacijam:
Gastrointestinal signs (vomiting, diarrhoea, inappetence) and lethargy are also common adverse reactions following treatment in such dogs.
Gastrointestinalni znaki (bruhanje, driska, neješčnost) in letargija so pogosti neželeni učinki zdravljenja pri takih psih.
The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see also sections 4 and 8).
Uporaba zdravila mora istočasno temeljiti na potrjenih ocenah mešanih okužb (ali tveganje za okužbe, kjer se uporablja preventiva) (glejte poglavji 4 in 8).
When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication.
Če pri zdravljenju parazitarne bolezni zamenjamo drugo vrsto pripravka z zdravilom Advocate, moramo pričeti z zdravljenjem v roku enega meseca po zadnjem nanosu.
Studies evaluating the pharmacokinetic behaviour of moxidectin after multiple applications have indicated that steady state serum levels are achieved following approximately 4 consecutive monthly treatments in cats.
Študije, ki so preučevale farmakokinetiko moksidektina po več aplikacijah, so pokazale, da se pri mačkah doseže stanje dinamičnega ravnovesja v serumu po približno 4 zaporednih mesečnih zdravljenjih.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Preprečite, da bi se psi kopali v stoječih vodnih ekosistemih 4 dni po nanosu.
The product should be administered monthly.
Zdravilo je treba dajati mesečno.
It is also active against gastrointestinal nematodes.
Deluje tudi na želodčno-črevesne nematode.
Loose debris should be gently removed from the external ear canal at each treatment.
Pri vsakem zdravljenju previdno odstranimo izločke in pršice iz zunanjega ušesnega kanala.
Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment.
Z zdravljenjem prenehamo pri psih, kjer ni vidnega izboljšanja zdravstvenega stanja oziroma, če je kožni ostružek po dveh mesecih zdravljenja še vedno pozitiven.